Actively Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Led by Alnylam Pharmaceuticals · Updated on 2026-05-01
158
Participants Needed
23
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
CONDITIONS
Official Title
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hepatocellular carcinoma confirmed by histology, cytology, or clinical criteria for patients with liver cirrhosis as per AASLD guidelines
- Received at least one prior systemic therapy for unresectable advanced or metastatic disease
- Presence of at least one WNT-pathway activating mutation
- Classified as Child-Pugh class A or B7
You will not qualify if you...
- Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors
- Presence of symptomatic extrahepatic disease
- Received anti-cancer therapy or investigational drugs within 3 weeks before the first dose of study drug
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
Clinical Trial Site
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Clinical Trial Site
La Jolla, California, United States, 92037
Actively Recruiting
3
Clinical Trial Site
Los Angeles, California, United States, 90033
Actively Recruiting
4
Clinical Trial Site
Jacksonville, Florida, United States, 32224
Actively Recruiting
5
Clinical Trial Site
Atlanta, Georgia, United States, 30322
Actively Recruiting
6
Clinical Trial Site
Chicago, Illinois, United States, 60637
Actively Recruiting
7
Clinical Trial Site
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
8
Clinical Trial Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
9
Clinical Trial Site
New York, New York, United States, 10029
Actively Recruiting
10
Clinical Trial Site
New York, New York, United States, 10032
Actively Recruiting
11
Clinical Trial Site
Cleveland, Ohio, United States, 44106
Actively Recruiting
12
Clinical Trial Site
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
13
Clinical Trial Site
Dallas, Texas, United States, 75390
Actively Recruiting
14
Clinical Trial Site
Houston, Texas, United States, 77030
Actively Recruiting
15
Clinical Trial Site
San Antonio, Texas, United States, 78229
Actively Recruiting
16
Clinical Trial Site
Richmond, Virginia, United States, 23298
Actively Recruiting
17
Clinical Trial Site
Milan, Italy, 20132
Actively Recruiting
18
Clinical Trial Site
Rozzano, Italy, 20089
Actively Recruiting
19
Clinical Trial Site
Verona, Italy, 37134
Actively Recruiting
20
Clinical Trial Site
Busan, South Korea, 49241
Actively Recruiting
21
Clinical Trial Site
Seongnam, South Korea, 13496
Actively Recruiting
22
Clinical Trial Site
Seongnam, South Korea, 13620
Actively Recruiting
23
Clinical Trial Site
Seoul, South Korea, 03722
Actively Recruiting
Research Team
A
Alnylam Clinical Trial Information Line
CONTACT
A
Alnylam Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here